+44 20 3868 9735
Objective: Currently, over 50 million people worldwide are diagnosed with Alzheimer’s Disease and more than 16 million Americans suffer from Mild Cognitive Impairment. Despite unremitting scientific and clinical efforts, there has yet to be therapy that has abated disease progression. In the last two decades, clinical trials have focused on beta amyloid (Aβ), which has been known to play a key role in the pathogenesis of AD; however, drug therapies in AD research have had a 99.6% failure rate.
Methods: In study NCT0360419, 3 MCI and 2 AD patients who met eligibility criteria underwent cognitive and physiological testing to test degrees of cognitive impairment, chronic inflammation and cellular health. All study patients were provided with a personalized Mito Food Plan and Cellular Repair Therapy.
Results: Improvements in cognitive testing scores and QOL were correlated to decreased inflammation.
Conclusion: Results suggest cognition can improve with the decrease of chronic inflammation in those with cognitive impairments.